The SynGAP Research Fund has awarded grants to Dr. Clement Chow for advancing therapeutic development for SYNGAP1-Related Disorders. Dr. Chow’s research utilizes a Drosophila model to screen drugs, leading to the identification of N-acetyl-L-leucine (NALL) as a potential treatment. A follow-up grant supports further studies on NALL’s therapeutic potential. This approach aims to accelerate the development of treatments by repurposing FDA-approved drugs. The research has the potential to provide immediate therapeutic benefits for SYNGAP1 patients and may also benefit other rare neurodevelopmental conditions. Dr. Chow’s collaborative approach and innovative research have the potential to make a significant impact on the lives of patients with SYNGAP1-Related Disorders.
Source link
Drug repurposing offers hope for SYNGAP1 patients
